SUBSCRIBE
SUBSCRIBE
News   Policy

Dr. Reddy’s Laboratories Ltd.'s Announces Settlement Of Imitrex® Litigation With GlaxoSmithKline

October 10, 2006 | 
1 min read
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE:RDY) announced today that it has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline’s Imitrex® tablets.
Legal Asia
GlaxoSmithKline
MORE ON THIS TOPIC
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
December 10, 2025
 · 
1 min read
 · 
Heather McKenzie
Microscope icon. Molecule and communication background. Connected lines with dots.
China
With Chinese Assets in Hand, Pharma Is Wondering What Else Can Be Learned
December 9, 2025
 · 
3 min read
 · 
Annalee Armstrong
Hands, tablet and doctor with body hologram, overlay and dna research for medical innovation on app. Medic man, nurse and mobile touchscreen for typing on anatomy study or 3d holographic ux in clinic
Policy
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
December 8, 2025
 · 
3 min read
 · 
Jennifer Smith-Parker
Pictured: CDC signage at its headquarters in Georg
Vaccines
CDC’s Vaccine Committee Recommends Delaying Hepatitis B Birth Dose
December 5, 2025
 · 
3 min read
 · 
Tristan Manalac